Integration of denosumab therapy in the management of giant cell tumors of bone.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32280167.
- Also identified by DOI 10.1016/j.jor.2020.03.020 and PMC identifier 7136643.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A review of the literature indicated denosumab is gaining favorability in the oncology community, particularly with increasing frequency in GCTB. Will denosumab be the breakthrough GCTB treatment? Here, we provide a pertinent case example, a review of the literature regarding the history and basic science behind the use of denosumab for GCTB, highlight the newest insights into the dosing and duration of treatment, and note advancements in the field.